Alliance for Clinical Trials in Oncology
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2011-01-01
- Employees
- 251
- Market Cap
- -
Clinical Trials
501
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (428 trials with phase data)• Click on a phase to view related trials
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
- Conditions
- Recurrent Non-Muscle Invasive Bladder CarcinomaStage 0a Bladder Cancer AJCC v8Stage I Bladder Cancer AJCC v8
- Interventions
- Procedure: Biopsy of BladderProcedure: CystoscopyProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Biospecimen CollectionProcedure: Transurethral Resection of Bladder Tumor
- First Posted Date
- 2025-05-31
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 330
- Registration Number
- NCT07000084
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
- Conditions
- Head and Neck Squamous Cell CarcinomaStage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
- Interventions
- Drug: PlaceboDrug: ChemotheraphyRadiation: Radiation TherapyDrug: Analgesic AgentProcedure: Biospecimen CollectionOther: Survey Administration
- First Posted Date
- 2025-05-28
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 228
- Registration Number
- NCT06992427
- Locations
- 🇺🇸
Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho, United States
🇺🇸Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho, United States
🇺🇸Kootenai Clinic Cancer Services - Sandpoint, Sandpoint, Idaho, United States
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- Conditions
- Castration-Sensitive Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
- Interventions
- Drug: Androgen TherapyProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Bone ScanProcedure: PSMA PET ScanProcedure: Biospecimen CollectionOther: Questionnaire Administration
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1260
- Registration Number
- NCT06931340
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Early Stage Breast Carcinoma
- Interventions
- Procedure: EchocardiographyProcedure: Multigated Acquisition ScanProcedure: MammographyProcedure: UltrasoundProcedure: Magnetic Resonance ImagingProcedure: Biospecimen CollectionOther: Questionnaire Administration
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1524
- Registration Number
- NCT06876714
Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8Anatomic Stage 1 Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Estrogen Receptor-Positive Breast CarcinomaHER2-Negative Breast Carcinoma
- Interventions
- Procedure: MammogramProcedure: Magnetic Resonance ImagingBiological: Dual X-ray AbsorptiometryProcedure: Biospecimen CollectionOther: Questionnaire Administration
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1156
- Registration Number
- NCT06671912
- Locations
- 🇺🇸
Katmai Oncology Group, Anchorage, Alaska, United States
🇺🇸Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 100
- Next
News
Dual Immunotherapy Combination Significantly Extends Survival in Advanced Cutaneous Squamous Cell Carcinoma
A phase II clinical trial demonstrated that combining avelumab and cetuximab nearly quadrupled median progression-free survival compared to avelumab alone in patients with advanced cutaneous squamous cell carcinoma.
Experts Debate Value of ctDNA Testing in Muscle-Invasive Bladder Cancer Management
Leading oncologists discuss the current limitations of circulating tumor DNA (ctDNA) testing in muscle-invasive bladder cancer, highlighting the need for more evidence before routine clinical implementation.
PROSPECT-Lung Trial Investigates Optimal Timing of Immunotherapy in Non-Small Cell Lung Cancer
The PROSPECT-Lung trial is evaluating whether immunotherapy is more effective when administered before or after surgery for resectable non-small cell lung cancer.
Veliparib Fails to Improve Survival in Glioblastoma Patients With MGMT Hypermethylation
A phase II/III trial evaluated the addition of veliparib to temozolomide in newly diagnosed glioblastoma patients with MGMT promoter hypermethylation.
myeloMATCH Trials Open to Accelerate Precision Medicine for AML and MDS
myeloMATCH, a collaborative effort by leading cancer research organizations, launches clinical trials to advance precision medicine for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).